



Allendale Centre East
 Suite 301, 6104-104 Street NW
 Edmonton | Alberta | T6H 2K7
 Phone: 1-877-431-4786
 www.asebp.ca

ENHANCED SPECIAL AUTHORIZATION REQUEST: Multiple Sclerosis

INSTRUCTIONS:

1. Please note that this form is to only be used by ASEBP covered members and their dependants. Members of the ARTA Retiree Benefits Plan do not need to use this form.
2. Please have your physician indicate whether this is an **INITIAL** enhanced special authorization request, a medication **CHANGE** request or a **RENEWAL** request by checking the appropriate box below and then completing **ONLY** the noted sections.
3. Part 2 must be completed by a specialist in the area of treatment.
4. Please have your physician submit the completed form to ASEBP by fax at 888-895-6837 or by email at SpecAuthHS@asebp.ca.
5. If you or your physician have any questions about the enhanced special authorization process, please contact our ASEBP Specialty Claims Coordinator at 780-431-4780.

TYPE OF REQUEST:

- | | | |
|---|--|--|
| <input type="checkbox"/> Initial
(complete Part 1, Part 2 A-E plus
physician signature) | <input type="checkbox"/> Change
(complete Part 1, Part 2 A-E plus
physician signature) | <input type="checkbox"/> Renewal
(complete Part 1, Part 2 A and F, plus
physician signature) |
|---|--|--|

Part 1: Patient Information *(to be completed by patient)*

A. Patient Information			
Last name:	First name:	ASEBP ID:	
Address:		Date of birth (YYYY/MM/DD):	
City:	Province:	Postal code:	Phone: ()
School jurisdiction (if patient is the covered member):		If you (the patient) are someone other than the covered member, please indicate your relation to the covered member: <input type="checkbox"/> Spouse <input type="checkbox"/> Dependant	
NOTE: Important notifications about your renewal will <i>only</i> be sent to the covered member email address used to register with My ASEBP. To register, visit www.asebp.ca/MyASEBP/ and follow the prompts.			
Coordination of Benefits			
Do you or your dependants have prescription drug coverage through another health benefits company, insurance company or another ASEBP plan? <input type="checkbox"/> Yes <input type="checkbox"/> No			
If yes, please complete below.			
Name of other health benefits company or insurance company:		Name of person holding coverage:	
Effective date of other coverage (YYYY/MM/DD):		Coverage holder date of birth (YYYY/MM/DD):	

Have you previously applied for funding or support from the manufacturer/patient assistance program for this medication?

Yes No

Please provide details and attach documentation of approval or declination:

The manufacturer/patient assistance program may have information which will be useful for your enhanced special authorization request, such as the verification of health and claims information related to your request. May ASEBP contact the manufacturer/patient assistance program to discuss or collect information related to your enhanced special authorization request?

Yes No

B. Consent to Collection, Use and Disclosure of Personal Health Information

The personal information contained in this form (with any supporting documentation provided) and other personal information held by the Alberta School Employee Benefit Plan (ASEBP) is used to determine eligibility for this benefit, to provide you with information regarding additional resources available to you through your benefits (e.g., Employee Family Assistance Program, Apple-a-Day) and administer the benefit plan. It may be necessary for ASEBP to disclose your personal information related to this notification to a third party service provider. When third party service providers are retained, appropriate contracts are in place to protect personal information.

I authorize my prescribing physician, pharmacist and/or the manufacturer/patient assistance program (if 'yes' was selected in the applicable area of the Coordination of Benefits section above) to disclose to ASEBP the information noted herein and any further information requested by ASEBP for the purpose of managing this enhanced special authorization request.

I understand why the information is required and am aware of the risks and benefits of providing this information. I consent to the collection, use and disclosure of my personal information for the purposes identified above. I understand that I may revoke my consent at any time and acknowledge that doing so will affect my/our eligibility to receive benefits related to this special authorization request.

I agree this authorization shall be in effect from the date below and shall be valid for the duration of time required to manage this request.

I understand that by virtue of the provisions of the *Personal Information Protection Act* of Alberta, my dependants are deemed to consent to the collection, use and disclosure of their personal information for the purpose of enrolment in and coverage under the group benefit plans, through me as the applicant.

I agree to the above and declare that my statements in this form are complete, accurate and true.

VERBAL CONSENT WILL NOT BE ACCEPTED, FORM MUST BE SIGNED BY PATIENT OR PARENT/GUARDIAN.

Patient signature: _____ Date: _____

If patient is a minor, parent/guardian signature: _____

Consent is being obtained in accordance with sections 7, 8, 9 and 61 of the Personal Information Protection Act of Alberta, Schedule 1 of the federal Personal Information Protection Electronic Documents Act and, in relation to personal health information, section 34 of the Health Information Act of Alberta. If you have any questions regarding the collection, use or disclosure of your personal information, please refer to our website at www.asebp.ca or contact the Privacy Officer at po@asebp.ca or 780-438-5300.

Part 2: Clinical Information (to be completed by prescribing physician; must be a specialist in area of treatment)

A. Prescriber Information			
Prescriber name:		CPSA #:	
Address:		Specialty:	
City:	Province:	Phone:	Fax:
Postal code:			<i>Fax number must be provided with each request submitted.</i>

B. Medication Requested

INITIAL ONE-YEAR COVERAGE for the treatment of multiple sclerosis (MS).

MS disease modifying therapy (DMT) requested:

- Aubagio (teriflunomide) Betaseron/Extavia (interferon beta-1b) Rebif (interferon beta-1a)
 Tecfidera (dimethyl fumarate) Avonex (interferon beta-1a) Copaxone (glatiramer acetate)
 Other: _____

This request is a: New request Restart request MS DMT switch

Drug strength(s): Please specify if titration is required and drug strengths necessary.

Directions for use (frequency or schedule, if appropriate (e.g., at 0, six, eight weeks, etc.):

C. Clinical Information

Diagnosis:

- Relapsing-remitting multiple sclerosis
 Secondary-progressive multiple sclerosis with relapses
 Other (please specify): _____

Is this medication for an off-label use?

- Yes No

Date of initial diagnosis:

Month _____ Year _____

Anticipated duration for treatment (max. approval is one year):

Does patient have any relevant drug allergies?

- Yes No

Nature of allergy, if applicable:

Current patient weight:

Most recent Expanded Disability Status Scale (EDSS) score: _____ Date: ____/____/____

Previous EDSS score (if available): _____ Date: ____/____/____

Qualifying relapses/attacks: Please provide dates of most recent relapses/attacks (*an attack is defined as the appearance of new symptoms or worsening of old symptoms, lasting at least 24 hours in the absence of fever, and preceded by stability for at least one month*).

Date of Relapse (YYYY/MM/DD)	Type of Relapse (One MRI relapse may substitute for one clinical relapse)
/ /	<input type="checkbox"/> Clinical relapse <input type="checkbox"/> MRI relapse (T1 gadolinium-enhancing lesions(s)) <input type="checkbox"/> Other: _____
/ /	<input type="checkbox"/> Clinical relapse <input type="checkbox"/> MRI relapse (T1 gadolinium-enhancing lesions(s)) <input type="checkbox"/> Other: _____
/ /	<input type="checkbox"/> Clinical relapse <input type="checkbox"/> MRI relapse (T1 gadolinium-enhancing lesions(s)) <input type="checkbox"/> Other: _____
/ /	<input type="checkbox"/> Clinical relapse <input type="checkbox"/> MRI relapse (T1 gadolinium-enhancing lesions(s)) <input type="checkbox"/> Other: _____

If this is NOT a new request:

Has the patient been on MS DMT since the relapse(s)? No Yes

Indicate if there have been any interruptions in therapy since starting MS DMT: No Yes; indicate:

- a. Reason for interruption of therapy: _____
- b. Time period of interruption: From (YYYY/MM/DD): ____/____/____ To (YYYY/MM/DD): ____/____/____
- c. How many relapses did the patient experience while off therapy? _____

Please provide all relevant clinical information to support medical necessity of drug therapy requested including any relevant lab tests which may support choice/monitoring of drug therapy:

Lab tests attached/scanned: Yes No

Please scan/attach any additional information that may be relevant in atypical cases that support the drug therapy choice.

D. Criteria for Initial Coverage

Prior/Current medication therapies				
Drug Name	Dosing Regimen	Start Date (YYYY/MM)	End Date (YYYY/MM)	Patient Response (if discontinued, provide details of intolerance, contraindication, or failure at maximum dose)
		/	/	
		/	/	
		/	/	
		/	/	
		/	/	

If a switch to a different DMT is requested, please provide reason:

E. All Other Medical Conditions and Drug Therapies Relevant to Your Health State

Condition/Diagnosis	Date Diagnosed (YYYY/MM)	Current Medications
	/	
	/	
	/	
	/	

F. Renewal Coverage Criteria

Requested drug, dose and interval: Drug name: _____ Dose: _____mg Interval: _____	Date patient started current medication: Month _____ Year _____	Anticipated duration for treatment (max. approval is one year):	Current patient weight:
--	---	---	-------------------------

Evidence of continued benefit (improvement or stabilization) as shown by at least ONE of the following:

Reduction in relapse/attack rate (decrease from _____ relapses/attacks per year to _____ relapses/attacks per year)

Improvement or stability of EDSS score
 Most recent EDSS score: _____ Date: ____ / ____ / ____
 Previous EDSS score: _____ Date: ____ / ____ / ____

MRI scan: reduction or stability in lesion load

MRI scan: reduction in gadolinium enhancing lesions

Overall clinical impression of benefit (please provide details):

Please provide any additional comments regarding patient's current medical status as applicable:

Please provide details explaining a lapse, for any period of more than 120 days, of the request medication during the previous approval period.

Please be advised further information may be requested if needed to facilitate determination of coverage.

Prescribing physician signature: _____ Date: ____ / ____ / ____